European regulators recommend rejection of Merck’s Covid-19 drug molnupiravir
European regulators recommended the EMA reject Merck’s Covid antiviral, saying that there’s not enough evidence it works in patients.
Merck and partner Ridgeback Biotherapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.